Twin Anemia-Polycythemia Sequence After Laser Therapy
A monochorionic diamniotic twin pregnancy was treated with fetoscopic laser photocoagulation at 19 weeks for twin-twin transfusion syndrome. At 28 weeks, ultrasound shows twin A with middle cerebral artery peak systolic velocity (MCA-PSV) of 1.7 multiples of the median and a small, echogenic liver; twin B has MCA-PSV of 0.7 MoM with cardiomegaly and tricuspid regurgitation. Amniotic fluid volumes are normal in both sacs. The referring team requests an urgent pathology consult on the significance of these findings and the optimal timing of delivery. There is no hydrops in either twin. The placenta is not yet available for examination.
1. Interpret the discordant MCA-PSV values in the context of prior laser therapy. What diagnosis best explains this, and how does it differ from recurrent TTTS?
Read the worked answer
The findings fit post-laser twin anemia-polycythemia sequence (TAPS): MCA-PSV >1.5 MoM in one twin (anemia, donor) and <1.0 MoM in the other (polycythemia, recipient), with normal amniotic fluid volumes in both sacs. This is the key discriminator from recurrent TTTS, which produces the oligohydramnios/polyhydramnios sequence (deepest vertical pocket <2 cm in the donor sac and >8 cm in the recipient).
Post-laser TAPS arises from residual small-caliber placental anastomoses not closed at laser, allowing slow, chronic net transfusion of red cells without the large-volume shifts that drive amniotic fluid discordance. The anemic twin's liver may appear echogenic from extramedullary hematopoiesis. Because the anemia is chronic and develops over weeks, the polycythemic twin can develop cardiac strain (cardiomegaly, TR) from hyperviscosity and volume load.
Spontaneous (non-laser) TAPS can occur in monochorionic twins and is diagnosed by the same MCA-PSV criteria. Pathologic correlation at delivery includes reticulocytosis and nucleated RBCs in the anemic twin and congestion in the polycythemic twin.
2. The team asks whether to deliver now or continue surveillance. Outline the reasoning that would drive your recommendation, including the limits of the data.
Read the worked answer
Delivery timing is driven by gestational age and severity, not by the TAPS label alone. At 28 weeks, the risks of prematurity are substantial, so expectant management with intensive surveillance (serial MCA-PSV every 2–3 days, fetal echocardiography, growth assessment) is generally favored unless there is hydrops, severe cardiac decompensation, or progression to a critically low hemoglobin.
Reasoning points:
- No hydrops in either twin is a favorable feature; hydrops is the strongest trigger for intervention.
- The polycythemic twin's cardiomegaly/TR is concerning but may be managed with close monitoring; delivery before 32 weeks should be justified by deterioration, not by the MCA-PSV value alone.
- Options short of delivery include intrauterine transfusion to the anemic twin (with the caveat that transfusing the donor can worsen polycythemia/hyperviscosity in the recipient) or, in selected centers, repeat laser.
- Data limits: randomized evidence for post-laser TAPS management is sparse; most recommendations come from observational cohorts. Antenatal MCA-PSV correlates imperfectly with postnatal hematocrit, so postnatal confirmation (cord blood hematocrit, reticulocyte count, blood smear) is essential.
A defensible plan: continue surveillance with a low threshold for delivery around 32–34 weeks or earlier if hydrops or cardiac decompensation develops, and plan paired cord blood sampling at delivery.
3. At delivery at 33 weeks, the anemic twin has cord hematocrit 22% with 12% nucleated RBCs; the polycythemic twin has hematocrit 72%. What placental findings would you expect, and what postnatal management issues should the pathologist flag?
Read the worked answer
Placental findings in TAPS are typically subtle: the two placental shares are often similar in size and color, unlike the classic pale/plethoric dichorionic appearance of acute TTTS. You may see mild pallor of the donor share and congestion of the recipient share, but the absence of striking color difference does not exclude TAPS. Injection studies may reveal residual small anastomoses.
Postnatal issues to flag:
- Anemic twin: high nucleated RBC count and reticulocytosis indicate chronic intrauterine anemia with active marrow response; monitor for hyperbilirubinemia and thrombocytopenia.
- Polycythemic twin: hematocrit 72% creates hyperviscosity risk - poor perfusion, hypoglycemia, necrotizing enterocolitis, renal vein thrombosis, and seizures. Partial exchange transfusion may be indicated for symptomatic hyperviscosity, though evidence for asymptomatic partial exchange is weak.
- Both twins need paired hematocrit comparison and follow-up for neurodevelopmental outcome, since chronic anemia and polycythemia each carry risk.
The pathologist's role is to document placental share, vascular anastomoses, and cord insertions, and to communicate that normal-appearing placentas do not argue against TAPS.